

Respondents	Number of respondents	Number of responses/ respondent	Average burden/ response (in hrs.)	Total burden (in hrs.)
Manual Entry Registration Form	500	1	0.083	41.5
Scantron Registration Form	500	1	0.083	41.5

Dated: May 29, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-14531 Filed 6-3-97; 8:45 am]

BILLING CODE 4163-18-P

Dated: May 28, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-14524 Filed 6-3-97; 8:45 am]

BILLING CODE 4163-18-P

Dated: May 29, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-14523 Filed 6-3-97; 8:45 am]

BILLING CODE 4160-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreements for Community-Based Primary Prevention Programs to Prevent Intimate Partner Violence for a Safe America, Program Announcement 727: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Community-Based Primary Prevention Programs to Prevent Intimate Partner Violence for a Safe America, Program Announcement 727.

Time and Date: 8:30 a.m.-5 p.m., June 24-25, 1997.

Place: Ramada Plaza Hotel, 4001 Presidential Parkway, Atlanta, Georgia 30341.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 727.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463.

Contact Person for More Information: James S. Belloni, Associate Director, State and Community Activities, National Center for Injury Prevention and Control, CDC, M/ S K02, 4770 Buford Highway, NE, Atlanta, Georgia 30341-3724, telephone 770/488-4538.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Determination of Optimal Frequency and Minimum Power Requirements for a New Radio-Frequency-Controlled Electrical Injury Protection System study protocol peer review.

Time and Date: 8:30-11:30 a.m., June 24, 1997.

Location: Suncrest Facility, Large Conference Room, NIOSH, CDC, 3040 University Avenue, Morgantown, West Virginia 26505.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: Participants will provide NIOSH with their individual advice and comments regarding technical and scientific aspects of the NIOSH protocol Determination of Optimal Frequency and Minimum Power Requirements for a New Radio-Frequency-Controlled Electrical Injury Protection System. Peer review panelists will review the study protocol and provide individual advice on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other governmental agencies, and the public are invited.

CONTACT PERSON FOR ADDITIONAL INFORMATION: Shengke Zeng, NIOSH, CDC, M/S 119, 1095 Willowdale Road, Morgantown, West Virginia 26505, telephone (304) 285-5971.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N-0180]

Agency Information Collection Activities: Proposed Collection; Comment Request; Reinstatement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish a notice in the **Federal Register** concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on requirements relating to the preapproved or emergency shipment of a blood product for manufacturing prior to completion of hepatitis B surface antigen (HBsAg) testing and shipment of a blood product for manufacturing when the donor is known to be reactive for HBsAg.

DATES: Submit written comments on the collection of information by August 4, 1997.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Margaret R. Wolff, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600